Meningitis, a rare but dangerous inflammation of the brain lining, made headlines in March 2026 after 21 confirmed cases and two deaths were reported in Kent. The outbreak was linked to a strain known as MenB, believed to have started in a nightclub in Canterbury affecting primarily students of a median age of 19 from the nearby University of Kent. While dangerous, its impact can be dampened with early treatment and vaccination.
The Ministry of Health explained that the meningococcal bacteria in question are normally present in the nasal and throat pathways, passed on through the air or via saliva. Only in rare cases does the bacteria enter the bloodstream and cause meningitis or septicaemia, a blood infection with fatal or life-altering effects.
Symptoms include fever, fatigue, muscle pain, confusion, and, in some cases, rashes or seizures. Infants might experience drops in energy, irritability, stiffness, or bulging soft spots on their heads. Given its life-threatening potential, anyone suspected of infection require immediate medical attention and antibiotic treatment.
Who can get the jab?
The Ministry of Health notes that like with many other bacterial infections, a vaccine can protect particularly vulnerable individuals, such as babies and immuno-compromised individuals.
In Luxembourg, the MenB vaccine is recommended and fully reimbursed for babies under one year old, while additional vaccines covering other strains (MenA, MenC, MenW, and MenY) are advised for children older than one year, as well as a booster shot before 15.
The Ministry further specified that due to the outbreak, those studying in the United Kingdom also qualify for a free vaccine as a precautionary measure. Otherwise, adults can also get the jab upon consultation with a doctor; however, the meningitis vaccine will not be reimbursed.
How effective is it?
The vaccine has proven particularly effective, reducing severe infections by around 75% since its introduction. The vaccine itself offers protection for 36 months.
In Luxembourg, the number of cases have remained limited, with a total of 18 reported between 2020 and 2024 and no related deaths recorded. Patients were on average 30 years old, with a high number of infections in the 15–34 age group.
While shortages have been reported in the UK following the March 2026 outbreak, the European Medicines Agency has yet to declare a shortage in the Grand Duchy.
